Results without
the yo-yo.

GLP-1 protocols with structured dose titration. Clinically validated dual- and triple-agonists. Lean-mass preserving. Designed for adults who want results without the yo-yo. Our catalog covers the dual-agonist with the clearest clinical track record — tirzepatide — and the triple-agonist investigational compound redefining the category, retatrutide. Studies have explored appetite regulation, insulin sensitivity, and, in the triple-agonist case, direct energy expenditure through glucagon receptor activity.